BR112016008086A2 - Glicoproteínas recombinantes e usos das mesmas - Google Patents
Glicoproteínas recombinantes e usos das mesmasInfo
- Publication number
- BR112016008086A2 BR112016008086A2 BR112016008086A BR112016008086A BR112016008086A2 BR 112016008086 A2 BR112016008086 A2 BR 112016008086A2 BR 112016008086 A BR112016008086 A BR 112016008086A BR 112016008086 A BR112016008086 A BR 112016008086A BR 112016008086 A2 BR112016008086 A2 BR 112016008086A2
- Authority
- BR
- Brazil
- Prior art keywords
- recombinant
- glycoproteins
- galactosidase
- recombinant glycoproteins
- methods
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title abstract 6
- 108090000288 Glycoproteins Proteins 0.000 title abstract 6
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 abstract 3
- 102000043404 human GLA Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70592—CD52
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894879P | 2013-10-23 | 2013-10-23 | |
| US201361901942P | 2013-11-08 | 2013-11-08 | |
| PCT/US2014/061789 WO2015061464A2 (en) | 2013-10-23 | 2014-10-22 | Recombinant glycoproteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016008086A2 true BR112016008086A2 (pt) | 2017-10-03 |
Family
ID=51871299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016008086A BR112016008086A2 (pt) | 2013-10-23 | 2014-10-22 | Glicoproteínas recombinantes e usos das mesmas |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11208644B2 (https=) |
| EP (2) | EP3060660B1 (https=) |
| JP (2) | JP6837334B2 (https=) |
| KR (2) | KR102479886B1 (https=) |
| CN (3) | CN105916984A (https=) |
| AU (2) | AU2014340152A1 (https=) |
| BR (1) | BR112016008086A2 (https=) |
| CA (1) | CA2927852A1 (https=) |
| CL (1) | CL2016000961A1 (https=) |
| CR (1) | CR20160225A (https=) |
| DK (1) | DK3060660T3 (https=) |
| DO (1) | DOP2016000079A (https=) |
| EA (1) | EA034515B1 (https=) |
| ES (1) | ES2882562T3 (https=) |
| HR (1) | HRP20211197T1 (https=) |
| HU (1) | HUE055236T2 (https=) |
| IL (2) | IL245255B (https=) |
| LT (1) | LT3060660T (https=) |
| MX (1) | MX392532B (https=) |
| MY (2) | MY197247A (https=) |
| NZ (1) | NZ720384A (https=) |
| PE (1) | PE20160723A1 (https=) |
| PH (1) | PH12016500708B1 (https=) |
| PL (1) | PL3060660T3 (https=) |
| PT (1) | PT3060660T (https=) |
| RS (1) | RS62171B1 (https=) |
| SG (2) | SG11201602932WA (https=) |
| SI (1) | SI3060660T1 (https=) |
| TN (1) | TN2016000140A1 (https=) |
| TW (3) | TW202332774A (https=) |
| UA (1) | UA119857C2 (https=) |
| UY (1) | UY35794A (https=) |
| WO (1) | WO2015061464A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| AU2017266932B2 (en) * | 2016-05-18 | 2023-04-20 | Modernatx, Inc. | Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease |
| CA3039673A1 (en) | 2016-10-20 | 2018-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| TW201829770A (zh) * | 2017-01-10 | 2018-08-16 | 美商阿米庫斯醫療股份有限公司 | 用於治療fabry氏病之重組α-半乳糖苷酶A |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| JP4001925B2 (ja) * | 1996-09-13 | 2007-10-31 | トランスカーヨティック セラピーズ インク． | α―ガラクトシダーゼＡ欠損症の治療 |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US20020081654A1 (en) * | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7133354B2 (en) | 2002-08-26 | 2006-11-07 | Qualcomm Incorporated | Synchronization techniques for a wireless system |
| DE60335024D1 (de) * | 2002-12-23 | 2010-12-30 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
| CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
| WO2008120107A2 (en) * | 2007-04-03 | 2008-10-09 | Oxyrane (Uk) Limited | Glycosylation of molecules |
| AU2008291358A1 (en) | 2007-08-31 | 2009-03-05 | F. Hoffmann-La Roche Ag | Glycosylation profile analysis |
| US9034341B2 (en) * | 2009-04-20 | 2015-05-19 | Transtech Pharma, Llc | Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions |
| WO2011107990A1 (en) * | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| US20120178105A1 (en) | 2011-01-10 | 2012-07-12 | Genzyme Corporation | Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich |
| CN103443270B (zh) * | 2011-01-20 | 2017-06-06 | 普罗塔里克斯有限公司 | 用于在植物和植物细胞中表达α‑半乳糖苷酶的核酸构建体 |
| JP6329483B2 (ja) * | 2011-10-12 | 2018-05-23 | シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． | 組換えヒトｎａｇｌｕタンパク質およびその利用 |
| EP2620506A1 (en) | 2012-01-25 | 2013-07-31 | Arla Foods Amba | Method of producing a galacto-oligosaccharide-containing composition |
| TWI528785B (zh) | 2013-02-08 | 2016-04-01 | 瑞昱半導體股份有限公司 | 立體影像的調整裝置及其方法 |
| SG10201709131UA (en) | 2013-03-08 | 2017-12-28 | Genzyme Corp | Continuous purification of therapeutic proteins |
-
2014
- 2014-10-21 TW TW111139854A patent/TW202332774A/zh unknown
- 2014-10-21 TW TW103136272A patent/TWI642782B/zh active
- 2014-10-21 TW TW107130267A patent/TWI793159B/zh active
- 2014-10-22 CN CN201480070424.3A patent/CN105916984A/zh active Pending
- 2014-10-22 KR KR1020217027690A patent/KR102479886B1/ko active Active
- 2014-10-22 US US15/030,555 patent/US11208644B2/en active Active
- 2014-10-22 DK DK14796346.6T patent/DK3060660T3/da active
- 2014-10-22 WO PCT/US2014/061789 patent/WO2015061464A2/en not_active Ceased
- 2014-10-22 EA EA201690826A patent/EA034515B1/ru not_active IP Right Cessation
- 2014-10-22 MY MYPI2019005029A patent/MY197247A/en unknown
- 2014-10-22 ES ES14796346T patent/ES2882562T3/es active Active
- 2014-10-22 PE PE2016000543A patent/PE20160723A1/es unknown
- 2014-10-22 SG SG11201602932WA patent/SG11201602932WA/en unknown
- 2014-10-22 RS RS20210960A patent/RS62171B1/sr unknown
- 2014-10-22 MX MX2016005321A patent/MX392532B/es unknown
- 2014-10-22 PL PL14796346T patent/PL3060660T3/pl unknown
- 2014-10-22 BR BR112016008086A patent/BR112016008086A2/pt not_active Application Discontinuation
- 2014-10-22 CN CN202110161563.9A patent/CN112852784A/zh active Pending
- 2014-10-22 JP JP2016526026A patent/JP6837334B2/ja active Active
- 2014-10-22 CA CA2927852A patent/CA2927852A1/en active Pending
- 2014-10-22 PT PT147963466T patent/PT3060660T/pt unknown
- 2014-10-22 CN CN202210146800.9A patent/CN114606217A/zh active Pending
- 2014-10-22 LT LTEPPCT/US2014/061789T patent/LT3060660T/lt unknown
- 2014-10-22 NZ NZ720384A patent/NZ720384A/en unknown
- 2014-10-22 EP EP14796346.6A patent/EP3060660B1/en active Active
- 2014-10-22 SI SI201431857T patent/SI3060660T1/sl unknown
- 2014-10-22 KR KR1020167013333A patent/KR102298080B1/ko active Active
- 2014-10-22 PH PH1/2016/500708A patent/PH12016500708B1/en unknown
- 2014-10-22 HU HUE14796346A patent/HUE055236T2/hu unknown
- 2014-10-22 AU AU2014340152A patent/AU2014340152A1/en not_active Abandoned
- 2014-10-22 TN TN2016000140A patent/TN2016000140A1/en unknown
- 2014-10-22 MY MYPI2016700943A patent/MY178632A/en unknown
- 2014-10-22 EP EP20183936.2A patent/EP3778884A1/en active Pending
- 2014-10-22 SG SG10201803366PA patent/SG10201803366PA/en unknown
- 2014-10-22 HR HRP20211197TT patent/HRP20211197T1/hr unknown
- 2014-10-22 UA UAA201605455A patent/UA119857C2/uk unknown
- 2014-10-23 UY UY0001035794A patent/UY35794A/es not_active Application Discontinuation
-
2016
- 2016-04-11 DO DO2016000079A patent/DOP2016000079A/es unknown
- 2016-04-21 CL CL2016000961A patent/CL2016000961A1/es unknown
- 2016-04-21 IL IL245255A patent/IL245255B/en active IP Right Grant
- 2016-05-17 CR CR20160225A patent/CR20160225A/es unknown
-
2020
- 2020-01-17 JP JP2020005541A patent/JP7296327B2/ja active Active
- 2020-02-11 IL IL272609A patent/IL272609B/en unknown
- 2020-12-21 AU AU2020294173A patent/AU2020294173A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/482,193 patent/US20220064617A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| BR112019004593A2 (pt) | mutações da proteína do envelope do hiv estabilizando o trímero | |
| BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
| BR122020006918B8 (pt) | Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| BR112017018975A2 (pt) | proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| BR112015005048A2 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
| BR112018001260A2 (pt) | mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição. | |
| BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
| GT201200252A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| BR112016008086A2 (pt) | Glicoproteínas recombinantes e usos das mesmas | |
| BR112016014876A2 (pt) | composto que modula a quantidade ou a atividade de gibspla2, composição farmacêutica, imunógeno que induz uma resposta imune anti-gibspla2, composição de vacina, método para o diagnóstico da imunodeficiência humana associada com a alteração de células t, e, método para a produção de gibspla2 | |
| BR112018010160A2 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
| BR112018067946A8 (pt) | Formulações tópicas contendo ciclosporina e usos das mesmas | |
| BR112017008962A2 (pt) | proteínas de fusão inibidoras de c1 esterase e usos das mesmas | |
| BR112019000837A2 (pt) | células miméticas de célula b | |
| BR112014031841A2 (pt) | formulação farmacêutica | |
| BR112015018265A2 (pt) | Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas | |
| BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023010057-3 PROTOCOLO 870230043547 EM 24/05/2023 12:11. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |